Making the offer of experimental treatments more widespread throughout the region with the use of monoclonal antibodies and the latest generation antiviral drugs, for the treatment of patients affected by Covid-19. This is the goal of the councilor for health, Mario Nieddu, who in a note sent to the health authorities of Sardinia specifies that he has identified "eleven structures authorized to prescribe therapies, a center for each local health authority to which the two university hospitals are added dell'Isola and the Brotzu Company ".
According to the latest AIFA monitoring, in the week from 13 to 19 January the number of prescriptions for monoclonal antibodies in Sardinia increased by 20% compared to the previous week. As regards antiviral drugs, Remdesivir and Molnupiravir are currently used in Sardinia, in accordance with what is authorized by Aifa. Since mid-January, antiviral treatments have grown by 118% with Molnupiravir (national average growth 70%) and by 27% for Remdesivir.
The administrations of antivirals and monoclonal antibodies are scheduled in hospitals and followed by specialized health personnel. The main target is that of subjects with risk factors with a high probability of hospitalization.
In detail, the authorized centers are: the Marino hospital of Alghero, the Giovanni Paolo II of Olbia, the Nostra Signora della Mercede in Lanusei, the San Francesco di Nuoro, the San Martino di Oristano, the Nostra Signora di Bonaria di San Gavino, the Cto di Iglesias, the San Pietro Clinics in Sassari, the Santissima Trinità and San Michele (Arnas G. Brotzu) in Cagliari and the Duilio Casula Polyclinic in Monserrato.
"Vaccination and good anti-contagion practices remain our most effective weapon", says Councilor Nieddu. "But in this war against the virus, the new drugs represent a useful tool to prevent more serious forms of the disease in the early stages in all those subjects who have one or more risk factors, such as in the case of cancer, diabetic, hypertensive or transplanted ".
(Unioneonline / vl)
